Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 174 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enzyme testing Clear all
Recruiting Phase 2 Interventional

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

NCT07698535
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 24, 2026, 10:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07591584
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions
FODMAP-targeting digestive enzyme blend, Placebo
Dietary Supplement · Other
Lead sponsor
Kiwi Health Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Suspended Phase 1Phase 2 Interventional

SN514-066b Enzyme in Deep Partial Thickness Burns

NCT06628037
View directory record Official record
Conditions
Burn Injury
Interventions
SN514-066b
Biological
Lead sponsor
SERDA bv
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NCT05053152
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
Procedure · Other · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
242
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 4 Interventional Results available

N-of-1 Trials In Children With Hypertension

NCT03461003
View directory record Official record
Conditions
Pediatric Hypertension
Interventions
NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 22 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 24, 2026, 10:18 PM EDT
Withdrawn No phase listed Observational

Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management

NCT01838265
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire, Short-Form 12 of Health Related Quality of Life Questionnaire, Memorial Anxiety Scale for Prostate Cancer, Plasma/Serum Sample for biomarkers, Urine Sample for Biomarkers, Blood Tests for Blood Urea Nitrogen and Creatinine, Blood Test for Serum PSA
Procedure · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NAD+ Oral Supplement Pilot Intervention in Adult Females

NCT06579209
View directory record Official record
Conditions
Cognitive Change, Inflammation, Neurodegenerative Diseases
Interventions
Treatment, Placebo
Dietary Supplement · Other
Lead sponsor
University of Rhode Island
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Kingston, Rhode Island • Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Recruiting Phase 2 Interventional

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06124157
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
366 Days to 46 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
145
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Not applicable Interventional

Evaluating an Emergency Department Observation Syncope Protocol for Older Adults

NCT01003262
View directory record Official record
Conditions
Syncope
Interventions
Emergency Department Observation Protocol, Unstructured, inpatient evaluation
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Royal Oaks, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 24, 2026, 10:18 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586
View directory record Official record
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Terminated Phase 1 Interventional

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

NCT01126502
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 4 Interventional Results available

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

NCT04718779
View directory record Official record
Conditions
Gaucher Disease
Interventions
Digital Engagement Application (GD App), No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 24, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

NCT01517984
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

NCT02556372
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
JKB-122
Drug
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 1 Interventional

Hyperhidrosis in Patients With Amputations-Botox

NCT03236012
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A (Botox)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Phase 4 Interventional Results available

Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings

NCT03302741
View directory record Official record
Conditions
Spasticity
Interventions
Botulinum neurotoxin (BTX), Physical Therapy, Standard BTX injection (ultrasound guided), 3-dimensional innervation zone (3DIZ) guided injection
Drug · Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 24, 2026, 10:18 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

NCT04175912
View directory record Official record
Conditions
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Carboplatin, Paclitaxel, Pevonedistat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
419
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 10:18 PM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 24, 2026, 10:18 PM EDT
Completed Early Phase 1 Interventional Results available

Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

NCT05266963
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CREON, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 10:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 24, 2026, 10:18 PM EDT